Lipotoxicity treatment with SGLT2 inhibitors in type 2 diabetes therapy
AbstractDysfunction of lipid metabolism, including impaired synthesis and production of adipokines, and obesity lead to the insulin resistance development and type 2 diabetes mellitus. The main purpose of this study is to evaluate the effectiveness of sodium-glucose cotransporter‑2 inhibitors therapy in treatment of both carbohydrate and lipid metabolism in patients with type 2 diabetes mellitus.
Keywords:adipokines; dapagliflozin; iSGLT2; adipose tissue; metabolically unhealthy obesity
Funding. The study had no sponsor support.
Conflict of interest. The author declares no conflict of interest.
For citation: Gogoleva S.P. Lipotoxicity treatment with SGLT2 inhibitors in type 2 diabetes therapy. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (3): 64–5. (in Russian)
DOI: https://doi.org/10.33029/2304-9529-2023-12-3-64-65 (in Russian)